California-based Agilent Technologies has announced the acquisition of BIOCIUS Life Sciences, a Massachusetts-based company that developed a spectrometry device, enabling “researchers to gain a fuller understanding of a drug’s biochemical properties, including potential liabilities in drug interactions.” Called Rapid Fire™, the device has reportedly been successful at screening “millions of compounds, providing results 10 to 100 times faster than traditional screening methods,” according to joint press release.

“BIOCIUS’ unique RapidFire technology gives customers an unsurpassed ability to increase the effectiveness and reduce the cost of drug discovery and compound identification,” said Agilent’s Gustavo Salem. “With this technology and the team that developed it now part of Agilient, we can expand our reach in the pharmaceutical and clinical mass spec markets.” See BIOCIUS/Agilent Press Release, March 1, 2011.